Operating CF
$9.46B
Capex
−$2.09B
Free Cash Flow
$7.38B
FCF Margin
+78.0%
Cash flow waterfall for Abbott Laboratories (ABT) — TTM through Q1 2026
Free cash flow: $7.38B
Cash flow breakdown for Abbott Laboratories (ABT) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $9.46B | $9.46B |
| Capital Expenditure | −$2.09B | $7.38B |
| Free Cash Flow | $7.38B | $7.38B |
| Acquisitions | −$19.90B | −$12.53B |
| Other Investing | −$287.00M | −$12.81B |
| Share Buybacks | −$793.00M | −$13.61B |
| Dividends Paid | −$4.19B | −$17.79B |
| Net Debt Change | $17.90B | $104.00M |
| Other Financing & FX | $167.00M | $271.00M |
| Net Cash Increase | $271.00M | $271.00M |
- Operating Cash Flow$9.46B
- Capital Expenditure−$2.09B
- Free Cash Flow$7.38B
- Acquisitions−$19.90B
- Other Investing−$287.00M
- Share Buybacks−$793.00M
- Dividends Paid−$4.19B
- Net Debt Change$17.90B
- Other Financing & FX$167.00M
- Net Cash Increase$271.00M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement